

**GOVERNMENT OF INDIA  
MINISTRY OF CHEMICALS & FERTILIZERS  
DEPARTMENT OF PHARMACEUTICALS**

RAJYA SABHA  
UNSTARRED QUESTION NO.527  
TO BE ANSWERED ON 23<sup>rd</sup> July, 2021

**Allocation of Amphotericin-B to State of Tamil Nadu**

**527 Shri P. Wilson:**

Will the Minister of **Chemicals and Fertilizers** be pleased to state:

- (a) whether Government has received any requests from Government of Tamil Nadu to increase the supply of Liposomal Amphotericin- B vials to the State and action taken thereon to supply these vials based on the request made by State Government;
- (b) the details of the number of vials of Liposomal Amphotericin- B supplied to State of Tamil Nadu;
- (c) the details of the number of Mucormycosis cases reported in States/UTs, especially in Tamil Nadu, district wise; and
- (d) whether Government has taken any action on the creation of artificial demands , hike in price for sale of Remdesivir drug in Tamil Nadu?

**ANSWER**

**MINISTER IN THE MINISTRY OF CHEMICALS & FERTILIZERS  
(SHRI MANSUKH MANDAVIYA)**

(a) and (b): Yes Sir, the government has received a letter dated 03.06.2021 from Chief Minister of Tamil Naidu requesting, to increase the supply of Liposomal Amphotericin-B in the State and for allocation of 30,000 vials to the State. Appropriate action has been taken to allocate and supply of the Liposomal Amphotericin- B vials to Tamil Nadu as per availability. The State has been allocated 98,620 vials against which the supply till 20<sup>th</sup> July 2021 is 76,610 vials based on purchase orders received by the suppliers

(c) The details of number of Mucormycosis cases (as on 19.07.2021) as uploaded by States / UTs on the portal maintained by the Ministry of Health and Family Welfare for reporting the Mucormycosis cases are given in the following table. For Tamil Nadu details are given district-wise.

	<b>Under treatment</b>	<b>Cured</b>	<b>Death</b>	<b>LAMA*</b>	<b>Total Cases</b>
<b>All States / UTs</b>	19,762	19,944	4,408	1,744	45,858
<b>Tamil Nadu (TN)</b>	2,203	1,503	339	83	4,128
<b>District wise</b>					
Chengalpattu	77	21	11	0	109
Chennai	874	225	99	1	1199
Coimbatore	141	105	65	31	342
Cuddalore	7	19	39	0	65
Dharmapuri	41	17	0	9	67
Dindigul	10	14	5	0	29

Erode	41	36	0	0	77
Kanchipuram	12	11	0	0	23
Kanniyakumari	18	0	2	0	20
Krishnagiri	14	48	3	4	69
Madurai	158	379	7	0	544
Nagapattinam	0	0	1	0	1
Namakkal	15	24	9	0	48
Perambalur	4	0	0	0	4
Pudukkottai	18	10	5	0	33
Ramanathapuram	0	1	0	0	1
Salem	273	121	0	6	400
Sivaganga	8	16	0	0	24
Thanjavur	84	139	58	20	301
Theni	24	0	1	0	25
Thiruvallur	0	0	0	0	0
Thiruvarur	31	0	0	0	31
Tiruchirappalli	21	238	14	3	276
Tirunelveli	61	30	8	0	99
Tiruppur	13	0	0	0	13
Tiruvannamalai	10	9	2	2	23
Tuticorin	18	37	5	3	63
Vellore	199	0	0	4	203
Villupuram	29	0	5	0	34
Virudhunagar	2	3	0	0	5
<b>TOTAL</b>	<b>2,203</b>	<b>1,503</b>	<b>339</b>	<b>83</b>	<b>4,128</b>

\*LAMA-Left Against Medical Advice

(d): National Pharmaceutical Pricing Authority (NPPA) and Drug Controller General of India (DCGI) have issued direction to all State Drug Controllers to take action against black marketing and hoarding of COVID-19 drugs. Further it is stated that Remdesivir is a non-scheduled formulation under Drug (Prices Control) Order, 2013 (DPCO). A manufacturer of a non-scheduled formulation (branded or generic) is at liberty to fix the maximum retail price launched by it. However, as per the DPCO, the manufacturers of non-scheduled formulations are not allowed to increase the maximum retail price of such formulations by more than 10% per annum. For existing lyophilised injections, MRPs of various brands varied up to Rs 5400/ per vial. However, on the intervention of the government, the major manufacturers/marketers of the Remdesivir Injection (a non-scheduled Drug) have voluntarily reduced its retail prices. However, on the intervention of government, the manufacturers have voluntarily agreed to reduce retail prices to less than Rs 3500/-. Accordingly, NPPA issued an Office Memorandum No. 37008/2021/Div.VI/NPPA dated 17<sup>th</sup> April 2021 indicating revised retail prices of the same and directed Drug Controllers of All State/UT Governments to ensure availability of the same at revised prices as shown in Table below:

**Table: Revised MRP of different brands of Remdesivir**

Name of Manufacturer	Brand Name	Old MRP (INR)	Revised MRP (INR)
Cadila Healthcare ltd	REMDAC	2800	899
Cipla Ltd.	CIPREMI	4000	3000

<b>Name of Manufacturer</b>	<b>Brand Name</b>	<b>Old MRP (INR)</b>	<b>Revised MRP (INR)</b>
Syngene International Limited (Biocon Biologics India)	RemWin	3950	2450
Dr. Reddy's Laboratories Ltd.	REDYX	5400	2700
Mylan Pharmaceuticals Pvt. Ltd.	DESREM	4800	3400
Hetero Healthcare Limited	COVIFOR	5400	3490
Jubilant Generics Ltd.	JUBI-R	4700	3400

\*\*\*\*\*